Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Psych MEQs / SAQsSpecialty psychiatry — sexual medicine interface

Psych MEQs / SAQs · Specialty psychiatry — sexual medicine interface

Female sexual interest/arousal disorder after SSRI treatment and comorbid dyspareunia (MEQ)

FRANZCP-style MEQ on FSIAD with SSRI contribution and pain interface: formulation, FSFI-informed assessment, antidepressant optimisation, psychosexual care, and selected pharmacologic adjuncts.

20 marks20 min1 min readVerification in progress

Target exams

FRANZCPMRCPsychABPNMD-DNB
On this page
Study tools

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 38-year-old woman with recurrent MDD is in partial remission (PHQ-9 = 9) on sertraline 150 mg orally daily for 8 months. She reports 7 months of markedly reduced sexual interest, reduced subjective arousal, and entry dyspareunia with avoidance of intimacy. She is distressed and fears her relationship will end. No alcohol binge pattern. Gynaecology review 1 year ago for heavy periods was unremarkable; she is perimenopausal-range irregular cycles. Partner is frustrated and has said she is 'broken.' (i) Formulate diagnoses and key differentials. (ii) Outline assessment. (iii) Propose a stepped management plan including psychosexual care and medication options with doses where relevant. (iv) Address relationship/safety and communication issues. (v) State prognostic and disposition points. (20 marks)

Write your answer

Saved on this device. No marking — you are the marker.

Model answer

Reveal model answerShowHide

(i) Formulation. Working diagnoses: female sexual interest/arousal disorder (FSIAD) pattern with clinically significant distress; likely substantial SSRI-associated sexual dysfunction (timeline with sertraline); acquired genito-pelvic pain (entry dyspareunia) possibly multifactorial (secondary pain from dryness/tension, perimenopausal tissue change, anxiety). Residual MDD. Psychosocial: partner criticism/coercive tone risk, relationship threat. Differentials: pure primary HSDD independent of drug; hyperprolactinaemia if other agents; thyroid disease; GSM/early atrophy; trauma-related avoidance; relationship-only problem without individual criteria (does not fit here given personal distress); infection/dermatosis needing gynaecology.[3][4][7]

(ii) Assessment. Confidential sexual history (lifelong vs acquired, generalised vs situational, desire/arousal/orgasm/pain, distress). MSE and suicide/relationship safety screen. Trauma, substances, contraception/fertility. Full medication review. FSFI for domains and baseline.[2] Targeted labs as indicated (TSH, prolactin if suggested, metabolic context). Gynaecology/pelvic floor referral for pain and perimenopausal symptoms; do not assume “psychogenic only.” Use Basson responsive-desire language to reduce shame.[1][7]

(iii) Stepped management. Psychoeducation; stop framing her as “broken.” Optimise depression and address sertraline with shared decision: careful dose reduction if safe, switch to lower sexual-burden agent, or adjunct bupropion SR 150 mg orally once daily titrating toward 150 mg orally twice daily if tolerated (exclude seizure risk, eating-disorder history).[3][4][5] Parallel sex therapy/CBT, couple sessions if safe, lubricants/moisturisers, consider local estrogen if GSM confirmed. If residual premenopausal HSDD after optimisation, discuss modest-benefit options such as flibanserin 100 mg orally at bedtime with no alcohol (availability regional) rather than as first step.[6][7] Pain pathway: physio and graded approaches if tension/vaginismus features emerge; avoid forced intercourse.[8]

(iv) Relationship/safety. Name the partner’s “broken” language as harmful; assess coercion/IPV. Prioritise consent. Offer couple work only if non-coercive. Safety-net for mood deterioration during antidepressant changes.[7]

(v) Prognosis/disposition. Many medication-related cases improve with regimen change; residual symptoms common. Outpatient psychiatry + sex therapy ± gynaecology/physio; review 4–8 weeks after medication changes; escalate if risk or refractory pain.[7]

References8ShowHide
  1. [1]Basson R The female sexual response: a different model J Sex Marital Ther, 2000.PMID 10693116
  2. [2]Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function J Sex Marital Ther, 2000.PMID 10782451
  3. [3]Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients J Clin Psychiatry, 2001.PMID 11229449
  4. [4]Serretti A, Chiesa A Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis J Clin Psychopharmacol, 2009.PMID 19440080
  5. [5]Segraves RT, Clayton A, Croft H, et al. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women J Clin Psychopharmacol, 2004.PMID 15118489
  6. [6]Katz M, DeRogatis LR, Ackerman R, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial J Sex Med, 2013.PMID 23672269
  7. [7]Clayton AH, Goldstein I, Kim NN, et al. The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women Mayo Clin Proc, 2018.PMID 29545008
  8. [8]ter Kuile MM, Melles R, de Groot HE, et al. Therapist-aided exposure for women with lifelong vaginismus: a randomized waiting-list control trial of efficacy J Consult Clin Psychol, 2013.PMID 24060195
Psychiatry Fellowship Pro

$29/ monthor $279 / year

The complete Psychiatry Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousErectile disorder and premature ejaculation — assessment and management (MEQ)Specialty psychiatry — sexual medicine interfaceNextExpert evidence and forensic report writing (MEQ)Forensic psychiatry — expert evidence